Related Experiment Video

Updated: Mar 16, 2026

Techniques to Induce and Quantify Cellular Senescence
06:51

Techniques to Induce and Quantify Cellular Senescence

Published on: May 1, 2017

35.4K

Integrative Approaches to Treating Cellular Senescence in Kidney Disease

Tomoka Misawa1, Amruta A2, LaTonya J Hickson3,4

  • 1School of Chemical Engineering, The University of Queensland, Brisbane, Queensland, Australia.

Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|March 14, 2026
PubMed

Insights

Cellular senescence drives kidney disease progression. Novel therapies combining extracellular vesicles and longevity proteins show promise for safer, more effective kidney disease management by targeting multiple disease pathways.

Area of Science:

  • Nephrology
  • Gerontology
  • Cellular Biology

Background:

  • Cellular senescence is a key driver in acute kidney injury and chronic kidney disease progression.
  • Current senotherapy (senolytic/senomorphic drugs) shows efficacy but has limitations, including adverse effects and partial disease mitigation.
  • Aging kidney disease necessitates advanced therapeutic strategies beyond current unimodular treatments.

Purpose of the Study:

  • To review the role of cellular senescence in kidney disease, focusing on diabetic kidney disease.
  • To explore novel therapeutic strategies, including extracellular vesicles and longevity proteins (e.g., α-klotho, SIRT1), for kidney disease.
  • To discuss the potential of combination therapies targeting inflammation, tissue damage, and senescence for improved kidney disease management.

Main Methods:

  • Literature review of cellular senescence mechanisms in kidney disease.
  • Analysis of preclinical data on senolytic and senomorphic drugs.
  • Exploration of the therapeutic potential of extracellular vesicles and longevity proteins.
  • Evaluation of combination therapy approaches for aging kidney disease.

Main Results:

  • Cellular senescence significantly contributes to kidney fibrosis and disease progression.
  • Extracellular vesicles and longevity proteins offer novel mechanisms to regulate senescence and alleviate kidney fibrosis.
  • Combination therapies targeting multiple pathways show synergistic potential to overcome limitations of single-modality treatments.

Conclusions:

  • Targeting cellular senescence is crucial for managing kidney disease.
  • Combining extracellular vesicles with longevity proteins presents a promising avenue for advanced senotherapy.
  • Multimodal therapeutic strategies are essential for comprehensive and safe management of aging kidney disease.
Keywords:
cellular senescencecombination therapyextracellular vesiclekidney diseaselongevity proteinmesenchymal stem cell

More Related Videos

Induction and Validation of Cellular Senescence in Primary Human Cells08:18

Induction and Validation of Cellular Senescence in Primary Human Cells

Published on: June 20, 2018

18.2K
SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs07:39

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

Published on: June 28, 2019

25.4K

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
580
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
964
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
879
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
450
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
305
Replicative Cell Senescence02:15

Replicative Cell Senescence

3.4K